Representative(s):

Michelle Hirschtritt
mhirschtritt@exelixis.com
773-700-6003

Chris Calhoun
ccalhoun@exelixis.com
262-613-0166

Michelle Martin
mimartin@exelixis.com
414-810-8900

Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines. To ensure you have the latest clinical data, including links to our pivotal trial publications, and important product information, visit our website. 

Company website:
www.exelixis.com

Cabometyx (cabozantinib) tablets

• CABOMETYX is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
• CABOMETYX® (cabozantinib) is indicated for the treatment of patients with advanced renal cell carcinoma (RCC).
• CABOMETYX, in combination with nivolumab, is indicated for the first-line treatment of patients with advanced RCC.
• CABOMETYX is indicated for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible.

PRESCRIBING INFO
https://tinyurl.com/y3ouaouf

PRODUCT RESOURCES
https://tinyurl.com/yyuzu73f

EXELIXIS ACCESS SERVICES® (EASE)
https://tinyurl.com/y5z2rfy4